Pharmaceutical Logistics


Valuable and sensitive products require high levels of security and systematic control when it comes to logistics.

We design end-to-end solutions that cater for urgent, sensitive or complex pharma or healthcare needs, from moving critical dry-ice samples for clinical trials to the movement of radioactive medicine across Europe or stem cells needed for urgent operations. We have even supported Patient Home Care initiatives with complete roll-outs and one2one patient training swap outs, and reconfiguration of home testing kits.

We understand that when it’s got to happen, it is controlled, compliant and secure.

We know that the pharmaceutical industry is faced with challenges such as compliance, embracing digital manufacturing, improving quality and reliable deliveries.  Providing service and time-critical logistics solutions that offer on-time delivery, stability, and precision across Europe helps overcome some of these challenges.

We are specialists in pharmaceutical logistics solutions moving critical and sensitive products that support medical advances and patient well-being.  We provide fast, reliable and efficient end-to-end logistics solutions across Europe that enhance your supply chain by delivering your goods in a timely, safe and compliant manner:

  • Later collection times to enable faster and earlier delivery times the following day
  • In-house customs brokerage service
  • Delivering to the end destination at the right time
  • Valuable and sensitive products handled in a controlled and delicate way with security
  • Experience in handling Radioactive materials
  • Returns management solutions
  • Lifecycle track and trace
  • End-to-end quality control and data integrity
  • Follow the Good Distribution Practice and Good Manufacturing Practice
  • ISO compliance


Due to the recent directive to supply medical radioisotopes into the UK by air in the eventuality of a no-deal Brexit, Carousel have been extremely responsive and flexible to support Curium meet the time-sensitive nature of deliveries of certain short half-life products to enable continuity of healthcare during a potential period of uncertainty. We look forward to developing this relationship in the future